<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365781">
  <stage>Registered</stage>
  <submitdate>11/02/2014</submitdate>
  <approvaldate>17/02/2014</approvaldate>
  <actrnumber>ACTRN12614000182695</actrnumber>
  <trial_identification>
    <studytitle>Critical Evaluation of a Targeted Point of Care (POC) ROTEM (Registered Trademark) and Multiplate (Registered Trademark) Guided Coagulation and Haemostasis Management Programme in Cardiac Surgical Patients</studytitle>
    <scientifictitle>Critical Evaluation of a Targeted Point of Care (POC) ROTEM (Registered Trademark) and Multiplate (Registered Trademark) Guided Coagulation and Haemostasis Management Programme in Cardiac Surgical Patients</scientifictitle>
    <utrn />
    <trialacronym>N/A</trialacronym>
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coagulation and transfusion management in patients undergoing cardiac surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>ROTEM / Multiplate coagulation assessment and product transfusion protocol.
At 4 predefined time points a ROTEM/Multiplate panel of tests will be analysed:
1. Pre-operatively
2. 30 mins before coming off Cardiopulmonary Bypass
3. 10 mins after coming off CPB and after Protamine
4. On admission to ICU post-operatively

At each of these time points blood product replacement will be guided by the results.  There is a predefined and validated algorithm.

In addition further tests will be done 10 minutes after any haemostatic intervention.

Further testing can be done at clinician discretion - i.e. In the presence of on-going bleeding further testing will be performed.

Testing will cease once there is no further evidence of on-going bleeding .
</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood and Blood Product Transfusion Rates</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood and Blood Product Cost
This data will be accessed from GCUH Blood Bank database</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Events Rate - TACO / TRALI / MOF / ARF / Sepsis</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality at 30 / 60 / 90 days</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disturbances in Fibrogen and Platelet contribution to coagulation in the preoperative period.
This is assessed by analysing the results of ROTEM/Multiplate tests.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Functional Outcome:
Functional outcome - NYHA Class
Cardiac Function - Echocardiography at 6 weeks post-operatively</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients undergoing cardiac surgery</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age &lt; 18 years</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>De-identified data will be obtained from hospital managed patient records and results will be amalgamated into a customised secure excel spreadsheet. Prior to analysis data will be assessed for normality using Kolmogorov-Smirnov and Shapiro-Wilk tests.  Blood test results at different time points will be analysed using repeated measures ANOVA and Bonferroni post hoc test. The association between pre/peri-operative carboxy-haemoglobin and total bilirubin with post-operative cardiac function will be determined using either Pearson or Spearmans rank correlation. T-tests will test the effect of baseline (high or low) carboxy-haemoglobin/total bilirubin concentrations on event rates per person years (readmission, arrhythmia etc).

A prospective sample size calculation was performed based on decreased Fibrinogen level experienced post cardiac surgery for a desired power of 90% and a alpha of 5% a minimum total subject sample size of 26 patients is estimated.  To ensure validity we propose to recruit a minimum of 100 patients.

Statistical Package for the Social Sciences (SPSS) will be used to perform the statistical analysis.
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2014</anticipatedstartdate>
    <actualstartdate>29/06/2015</actualstartdate>
    <anticipatedenddate>1/03/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Gold Coast Hospital - Southport</hospital>
    <postcode>4215 - Southport</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Gold Coast University Hospital Critical Care Research Group</primarysponsorname>
    <primarysponsoraddress>1 Hospital Boulevard
Southport
QLD
4215</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Gold Coast University Hospital</fundingname>
      <fundingaddress>1 Hospital Boulevard
Southport
QLD
4215</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>There is an increasing body of evidence that the adoption of point of care (POC) guided coagulation and haemostatic management algorithms in the cardiac surgical patient population results in improved outcomes.

We aim to critically evaluate our POC programme at the Gold Coast University Hospital (GCUH). In addition, we aim to evaluate the prognostic importance of baseline and perioperative humeral factors relating to haem catabolism (bilirubin/carboxy haemoglobin) in modulating haemostatic function and predicting post-operative outcomes in patients undergoing cardiac surgery

 


</summary>
    <trialwebsite>N/A</trialwebsite>
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>N/A</publicnotes>
    <ethicscommitee>
      <ethicname>Gold Coast University Hospital HREC</ethicname>
      <ethicaddress>1 Hospital Boulevard
Southport
QLD
4215</ethicaddress>
      <ethicapprovaldate>26/03/2014</ethicapprovaldate>
      <hrec>EC00160</hrec>
      <ethicsubmitdate>12/02/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>James Winearls</name>
      <address>Gold Coast University Hospital
1 Hospital Boulevard
Southport
QLD
4215</address>
      <phone>+61756875684</phone>
      <fax />
      <email>james_winearls@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>James Winearls</name>
      <address>Gold Coast University Hospital
1 Hospital Boulevard
Southport
QLD
4215</address>
      <phone>+61756875684</phone>
      <fax />
      <email>james_winearls@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>James Winearls</name>
      <address>Gold Coast University Hospital1 Hospital Boulevard
Southport
QLD
4215</address>
      <phone>+61756875684</phone>
      <fax />
      <email>james_winearls@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Moira Arnell</name>
      <address>Gold Coast University Hospital
1 Hospital Boulevard
Southport
QLD
4215</address>
      <phone>+61756875717</phone>
      <fax />
      <email>moira.arnell@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>